# The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir.

> **NCT04258475** · PHASE4 · UNKNOWN · sponsor: **Ottawa Hospital Research Institute** · enrollment: 12 (estimated)

## Conditions studied

- Calcium Supplementation in HIV Patients Using Raltegravir

## Interventions

- **DRUG:** Raltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily.
- **DRUG:** Calcium carbonate antacid tablet

## Key facts

- **NCT ID:** NCT04258475
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-09
- **Primary completion:** 2024-06-15
- **Final completion:** 2025-01-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04258475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04258475, "The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04258475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*